Download PDF
Klin Monbl Augenheilkd 2016; 233(04): 488-489
DOI: 10.1055/s-0041-111805
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment

Rezidiv einer Chorioretinopathia centralis serosa unter Behandlung mit Vemurafenib und Cobimetinib
P. Kouros
1   Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding)
,
H. Gerding
1   Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding)
2   Department of Ophthalmology, University of Münster, Münster (Chairman: Prof. Dr. Nicole Eter)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 April 2016 (online)

Also available at
    Permissions and Reprints

Introduction

Mitogen-activated protein kinase (MAPK) inhibitor associated retinopathy (MAPK-retinopathy) resembling central serous chorioretinopathy (CSR) was described in few observational cohort-based studies [1], [2], [3] as well as in a case report [4]. Interestingly, the incidence of this complication seems to increase considerably under a combination of vemurafenib and cobimetinib as compared to vemurafenib monotherapy as was recently reported [2]. In this case symptoms of CSR started 3 days after introduction of vemurafenib and cobimetinib chemotherapy.

 

  • References

  • 1 van Dijk EH, van Herpen CM et al. Serous retinopathy associated with mitogen-activated protein kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology 2015; 122: 1907-1916
    CrossrefPubMedGoogle Scholar
  • 2 Larkin J, Ascierto PA et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
    CrossrefPubMedGoogle Scholar
  • 3 Urner-Bloch U, Urner M et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014; 25: 1437-1441
    CrossrefPubMedGoogle Scholar
  • 4 McCannel TA, Chmielowski B et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 2014; 132: 1005-1009
    CrossrefPubMedGoogle Scholar
  • 5 Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448
    CrossrefPubMedGoogle Scholar
  • 6 Imamura Y, Fujiwara T et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-1473
    CrossrefPubMedGoogle Scholar
  • 7 Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye 2010; 24: 1743-1756
    CrossrefPubMedGoogle Scholar
  • 8 Nicholson B, Noble J et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126
    CrossrefPubMedGoogle Scholar
  • 9 Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845
    PubMedGoogle Scholar
  • 10 Kitzmann AS et al. The incidence of central serous chorioretinopathy in Olmsted County, Minessota, 1980–2002. Ophthalmology 2008; 115: 169-173
    CrossrefPubMedGoogle Scholar